Olema Pharmaceuticals announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares in the offering are to be sold by Olema. The gross proceeds to Olema from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $190M. In addition, Olema has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 20, 2025, subject to the satisfaction of customary closing conditions. TD Cowen, Evercore ISI, Guggenheim Securities, LifeSci Capital, Oppenheimer & Co. and H.C. Wainwright & Co. are acting as book-running managers for the offering.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Oncology announces common stock and warrants offering, no amount given
- Olema Pharmaceuticals Terminates ATM Prospectus
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Positive Outlook for Olema’s OPERA-02 Study Following Roche’s Successful Phase 3 Trial Results
- Positive Outlook on Olema Pharmaceuticals’ Palazestrant Driven by Promising Trial Data and Market Potential